Business
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual ...
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.","length":414,"tagName":"p"},{"type":"text","content":"44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026","length":67,"tagName":"p"},{"type":"text","content":"Format: Company Presentation","length":28,"tagName":"p"},{"type":"text","content":"Day/Time: Tuesday, January 13 at 8:15 AM PST","length":44,"tagName":"p"},{"type":"text","content":"Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true","length":144,"tagName":"p"},{"type":"text","content":"If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.","length":134,"tagName":"p"},{"type":"text","content":"A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.","length":153,"tagName":"p"},{"type":"text","content":"About ProtagonistProtagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural ho...